Since the 50 s of the last century, labor charts have been proposed and appraised as a tool to diagnose labor abnormalities and guide decision-making. The partogram, the most widely adopted form of labor charts, has been endorsed by the world health organization (WHO) since 1994. Nevertheless, recent studies and systematic reviews did not support clinical significance of application of the WHO partogram. These results have led to further studies that investigate modifications to the structure of the partogram, or more recently, to reconstruct new labor charts to improve their clinical efficacy. This guideline appraises current evidence on use of labor charts in management of labor specially in low-resource settings.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2021.1946787DOI Listing

Publication Analysis

Top Keywords

labor charts
20
labor
8
charts management
8
management labor
8
charts
5
middle-east obgyn
4
obgyn graduate
4
graduate education
4
education mogge
4
mogge foundation
4

Similar Publications

The paper starts by describing the manufacturing process of cups thermoformed from extruded foils of 80% recycled PET (80r-PET), which comprises heating, hot deep drawing and cooling. The 80r-PET foils were heated up to 120 °C, at heating rates of the order of hundreds °C/min, and deep drawn with multiple punchers, having a depth-to-width ratio exceeding 1:1. After puncher-assisted deformation, the cups were air blown away from the punchers, thus being "frozen" in the deformed state.

View Article and Find Full Text PDF

Neuroimmunology is reshaping the understanding of the central nervous system (CNS), revealing it as an active immune organ rather than an isolated structure. This review delves into the unprecedented discoveries transforming the field, including the emerging roles of microglia, astrocytes, and the blood-brain barrier (BBB) in orchestrating neuroimmune dynamics. Highlighting their dual roles in both repair and disease progression, we uncover how these elements contribute to the intricate pathophysiology of neurodegenerative diseases, cerebrovascular conditions, and CNS tumors.

View Article and Find Full Text PDF

Background: Primary health care (PHC) systems and their successes and challenges vary between and within countries. We elucidate the role of PHC on health status and universal health coverage (UHC) by describing the achievements and challenges of PHC systems in seven countries representing the three economic levels: high-income (Belgium, Australia), middle-income (South Africa, Thailand), and low-income countries (Cambodia, Ethiopia, and Nepal).

Methods: We adopted a mixed-methods approach and (a) extracted quantitative data on the key health and universal health coverage index of countries and (b) conducted a scoping review of the PHC systems in these countries.

View Article and Find Full Text PDF

Not for everyone: Factors influencing who receives psychotherapy in people with multiple sclerosis.

Mult Scler Relat Disord

December 2024

Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address:

Background: Although depression and anxiety are common in people with multiple sclerosis (pwMS), access to psychotherapy remains limited.

Objectives: This study aimed to identify clinical factors that predict use of psychotherapy among pwMS.

Methods: From a retrospective chart review of a tertiary neuropsychiatry clinic in Toronto, Canada, data were obtained for 267 pwMS who received neuropsychiatric treatment (either with antidepressants or psychotherapy).

View Article and Find Full Text PDF

Background: Therapeutic advancements for the polyglutamine diseases, particularly spinocerebellar degeneration, are eagerly awaited. We evaluated the safety, tolerability, and therapeutic effects of L-arginine, which inhibits the conformational change and aggregation of polyglutamine proteins, in patients with spinocerebellar ataxia type 6 (SCA6).

Methods: A multicenter, randomized, double-blind, placebo-controlled phase 2 trial (clinical trial ID: AJA030-002, registration number: jRCT2031200135) was performed on 40 genetically confirmed SCA6 patients enrolled between September 1, 2020, and September 30, 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!